The Evolving Roles of Human iPSC-Derived Cardiomyocytes in Drug Safety and Discovery.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28686863.
- Also identified by DOI 10.1016/j.stem.2017.06.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nonclinical studies of drug effects with human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide new possibilities for evaluating drug safety and efficacy. The Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm provides lessons from the cardiac field that also apply to drug studies with other stem cell-based assays.
Medical subject headings
- Arrhythmias, Cardiac
- Drug Evaluation, Preclinical
- Induced Pluripotent Stem Cells
- Myocytes, Cardiac